| Literature DB >> 34033216 |
Hyun Woo Jeon1, Young-Du Kim1, Sung Bo Sim1, Mi Hyoung Moon2.
Abstract
BACKGROUND: Adenocarcinoma is the most common type of lung cancer and most adenocarcinomas have heterogeneous subtypes. Acinar-predominant adenocarcinoma is the most common. This study aimed to identify the prognostic impact of other mixed histological subtypes in acinar-predominant lung adenocarcinoma.Entities:
Keywords: cancer risk factors; lung cancer; surgery; surgical oncology
Mesh:
Year: 2021 PMID: 34033216 PMCID: PMC8287017 DOI: 10.1111/1759-7714.14013
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Baseline patient characteristics
| Characteristic | Total ( |
|---|---|
| Median (range) or n (%) | |
| Age | 62 (25–82) |
| Sex | Male: 85 (41) |
| Smoking | 58 (28.2) |
| CEA | 1.4 (0.22–14.19) |
| SUVmax | 2.4 (0–17.6) |
| GGO | 118 (54.9) |
| Procedure | |
| Lobectomy | 198 (92.1) |
| Segmentectomy | 17 (7.9) |
| VATS | 180 (83.7) |
Note: Data are presented as the median (minimum‐maximum) or frequencies and percentages as appropriate.
Abbreviations: CEA, carcinoembryonic antigen; GGO, ground‐glass opacity; SUVmax, maximum standardized uptake value; VATS, video‐assisted thoracoscopic surgery.
Pathological characteristics of stage IA acinar‐predominant subtype adenocarcinoma
| Characteristic | Total ( |
|---|---|
| Median (range) or n (%) | |
| Size | 1.8 (0.3–3) |
| Differentiation | |
| Well | 76 (35.3) |
| Moderate | 127 (59.1) |
| Poor | 12 (5.6) |
| Other histological subtype | |
| Papillary | 50 (23.3) |
| Lepidic | 154 (71.6). |
| MPP | 30 (14) |
| Solid | 24 (11.2) |
| Margin | 3.5 (0.1–10) |
| LVI | 60 (27.9) |
| Number of dissected LNs | 11 (0–37) |
| MLND | 179 (83.3) |
| pStage IA1 | 26 (12.1) |
| pStage IA2 | 114 (53) |
| pStage IA3 | 75 (34.9) |
| Adjuvant treatment | 3 (1.4) |
| Recurrence | 28 (13) |
| Death | 21 (9.8) |
Note: Data are presented as the medians (minimum‐maximum) or frequencies and percentages as appropriate.
Abbreviations: LN, lymph node; LVI, lymphovascular invasion; MLND, mediastinal lymph node dissection; MPP, micropapillary.
Clinical and pathological variables according to the proportion of lepidic subtype in stage IA acinar‐predominant lung adenocarcinoma
| Variables | Lepidic ≥20% | Lepidic <20% |
|
|---|---|---|---|
|
|
| ||
| Age | 63 (39–82) | 64 (25–82) | 0.567 |
| Sex (male) | 36 (34.3) | 49 (44.5) | 0.128 |
| Smoking | 22 (21) | 36 (32.7) | 0.065 |
| CEA | 1.4 (0.22–9) | 1.4 (0.5–14.19) | 0.076 |
| SUVmax | 2 (0–11.6) | 2.8 (0–17.60) | 0.001 |
| GGO | 67 (63.8) | 51 (46.4) | 0.013 |
| Lobectomy | 97 (92.4) | 101 (91.8) | 1.000 |
| VATS | 87 (82.9) | 93 (84.5) | 0.854 |
| Size | 1.8 (0.6–3) | 1.9 (0.3–3) | 0.553 |
| Well differentiated | 52 (49.5) | 24 (21.8) | <0.001 |
| Other mixed subtype | |||
| Papillary | 17 (16.2) | 33 (30) | 0.023 |
| MPP | 11 (10.5) | 19 (17.3) | 0.172 |
| Solid | 6 (5.7) | 18 (16.4) | 0.016 |
| Margin | 3.5 (0.1–7) | 3.5 (0.5–10) | 0.948 |
| Number of dissected LNs | 11 (0–32) | 11 (0–37) | 0.681 |
| LVI | 29 (27.6) | 31 (28.2) | 1.000 |
| Recurrence | 7 (6.7) | 21 (19.1) | 0.008 |
Note: Data are presented as the medians (minimum‐maximum) or frequencies and percentages as appropriate.
Abbreviations: CEA, carcinoembryonic antigen; GGO, ground‐glass opacity; LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value; VATS, video‐assisted thoracic surgery.
FIGURE 1Survival curves for (a) disease free survival and (b) overall survival for stage IA acinar‐predominant lung adenocarcinoma according to the proportion of lepidic subtype
Cox proportional analysis for disease‐free survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| SUVmax | 1.118 | 1.020–1.226 | 0.018 | 0.974 | 0.857–1.106 | 0.682 |
| CEA | 1.151 | 1.004–1.321 | 0.044 | 1.086 | 0.928–1.270 | 0.304 |
| Moderate differentiation | 10.037 | 2.382–42.299 | 0.002 | 6.801 | 1.597–28.966 | 0.010 |
| Solid subtype | 2.737 | 1.105–6.776 | 0.030 | 1.533 | 0.567–4.147 | 0.400 |
| Lepidic <20% | 3.060 | 1.300–7.200 | 0.010 | 2.621 | 1.065–6.452 | 0.036 |
| LVI | 3.568 | 1.691–7.528 | 0.001 | 3.244 | 1.409–7.470 | 0.006 |
Abbreviations: CEA, carcinoembryonic antigen; LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value.
Cox proportional analysis for overall survival
| Variables | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| SUVmax | 1.150 | 1.036–1.277 | 0.009 | 1.064 | 0.943–1.202 | 0.314 |
| Lepidic <20% | 2.521 | 0.976–6.513 | 0.056 | 2.430 | 0.903–6.536 | 0.079 |
| LVI | 2.920 | 1.233–6.915 | 0.015 | 2.624 | 1.010–6.820 | 0.048 |
Abbreviations: CEA, carcinoembryonic antigen; LVI, lymphovascular invasion; SUVmax, maximum standardized uptake value.